ESR1 and breast carcinoma: Then, we compared parthanatos pathway activation levels across different breast cancer subtypes and found that HER2-positive breast cancer exhibited significantly higher parthanatos pathway activation compared to TNBC and ER/PR + HER2- breast cancer (Figure S2A).